These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359 [TBL] [Abstract][Full Text] [Related]
51. Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Sun X; Chen C; Vessella RL; Dong JT Prostate; 2006 May; 66(6):660-6. PubMed ID: 16388502 [TBL] [Abstract][Full Text] [Related]
52. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815 [TBL] [Abstract][Full Text] [Related]
53. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916 [TBL] [Abstract][Full Text] [Related]
54. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. Wild PJ; Giedl J; Stoehr R; Junker K; Boehm S; van Oers JM; Zwarthoff EC; Blaszyk H; Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI; Hartmann A J Pathol; 2007 Jan; 211(1):18-25. PubMed ID: 17072825 [TBL] [Abstract][Full Text] [Related]
55. Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma. Diamantopoulou K; Lazaris A; Mylona E; Zervas A; Stravodimos K; Nikolaou I; Athanassiadou S; Nakopoulou L Anticancer Res; 2005; 25(6C):4543-9. PubMed ID: 16334139 [TBL] [Abstract][Full Text] [Related]
56. Molecular evidence supporting field effect in urothelial carcinogenesis. Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427 [TBL] [Abstract][Full Text] [Related]
57. [Urothelial neoplasms in individuals younger than 20 years show very few genetic alterations and have a favourable clinical outcome]. Giedl J; Wild PJ; Stoehr R; Junker K; Boehm S; van Oers JM; Zwarthoff EC; Blaszyk H; Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI; Hartmann A Verh Dtsch Ges Pathol; 2006; 90():253-63. PubMed ID: 17867604 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. Mylona E; Magkou C; Gorantonakis G; Giannopoulou I; Nomikos A; Zarogiannos A; Zervas A; Nakopoulou L Anticancer Res; 2006; 26(5A):3567-71. PubMed ID: 17094484 [TBL] [Abstract][Full Text] [Related]
59. Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Burger M; Burger SJ; Denzinger S; Wild PJ; Wieland WF; Blaszyk H; Obermann EC; Stoehr R; Hartmann A Eur Urol; 2006 Oct; 50(4):770-5; discussion 776. PubMed ID: 16762487 [TBL] [Abstract][Full Text] [Related]
60. [Transforming growth factor beta receptor II mutations in RER positive colorectal cancers]. Lai MD; Huang ZD; Huang Q; Chen J Zhonghua Bing Li Xue Za Zhi; 2004 Feb; 33(1):6-10. PubMed ID: 14989920 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]